PDE6C

Across TCGA pan-cancer cohorts, PDE6C Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PDE6C data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PDE6C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDE6C expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, UCEC, and LUAD are the cancer types where PDE6C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.075	0.533	<.001	12	view →
UCEC	DFS	Median	All	0.954	0.828	.027	10	view →
LUAD	DFS	Median	All	0.339	0.680	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PDE6C–ESCA (DFS)

Open the ESCA breakdown →